Leidos Biomedical Research Inc.

Leidos Biomedical Research Inc., a subsidiary of Leidos Holdings Inc., operates as a Federally Funded Research and Development Center (FFRDC) contractor delivering comprehensive biomedical research and facilities support services to the National Institutes of Health as a prime contractor. The company competes on a full-and-open basis without set-asides, commanding 98% of its 266 recent awards as prime contracts on cost-plus-fixed-fee and cost-plus-award-fee delivery orders.

Customer concentration is extreme and heavily tilted toward the National Cancer Institute (NCI). NCI accounts for 182 of 266 awards (68% by count) with $179.22 billion in combined potential value, representing 99% of the company's total contract footprint. The National Institute of Allergy and Infectious Diseases (NIAID) is the distant second customer with 72 awards valued at $2.84 billion combined potential value. The National Center for Advancing Translational Sciences, National Institute of Neurological Disorders and Stroke, and the FDA round out active customer agencies. This concentration is structural: Leidos Biomedical Research holds two master indefinite delivery vehicles — the NCI contract 75N91019D00024 ($7.08 billion potential value across 167 task orders) and NIAID contract HHSN261201500003I ($1.28 billion across 85 task orders) — from which the overwhelming bulk of recent awards flow as delivery-order task work.

The vendor's capability portfolio spans biomedical research execution, facilities infrastructure management, clinical trial support, and specialized manufacturing. Recent representative work includes a $805.99 million NCI operational task order (awarded August 2025, completion August 2027) covering research and operational support across multiple scientific domains; a $139.89 million NIAID operational task order (August 2025, completion August 2027) for infectious disease research and facility operations; a $173.28 million NIAID delivery order (June 2023, completion May 2028) for Phase 1 and Phase 2 vaccine clinical trials; a $31.997 million NIAID order (September 2022, completion August 2028) for clinical testing of influenza vaccines; and $22.4 million in NCI cancer therapeutics discovery and development work (September 2022, completion September 2027). The vendor also delivers specialized manufacturing work — recent examples include production of monoclonal antibodies, gene therapy vector manufacturing, vaccine platform development (including mRNA capability establishment valued at $30.32 million), and chemistry, manufacturing, and controls development of therapeutic candidates. Facilities work spans building renovations, infrastructure improvements, chilled water systems, elevator refurbishment, steam piping replacement, and compressed gas security at the Frederick National Laboratory for Cancer Research campus.

The vendor's place of performance is Frederick, Maryland, where Leidos Biomedical Research operates the Frederick National Laboratory for Cancer Research on behalf of NCI. Work also extends to subordinate NIH institutes and collaborative sites.

Service Contract Inventory reporting captures the vendor's invoiced federal service-contract activity at $2.64 billion across fiscal years 2022–2024, with FY2022 at $920.1 million, FY2023 at $966 million, and FY2024 at $749.1 million — a decline of roughly 22% year-over-year from FY2023 to FY2024. The vendor maintained a workforce of approximately 1,860 FTEs in FY2022, 1,831 in FY2023, and 1,830 in FY2024, indicating stable staffing across the reporting period. Government-paid hourly rates on SCI-reportable contracts ranged from a 10th percentile of $70.79/hr to a median of $191.71/hr, with senior labor and specialized research roles commanding up to the 90th percentile of $1,379.73/hr.

Across SCI-reportable prime contracts, the vendor engaged subcontractors for an average of 33% of total contractor hours, with 833 named subcontractors reported. The vendor performs significant work in-house but relies on a broad network of academic institutions, specialized equipment manufacturers, and operational support firms. Named subcontractors visible in recent award summaries include Abbott Molecular Inc. for molecular diagnostics, Tecan U.S. Inc. for laboratory automation, Brooks Instrument LLC for flow instrumentation, Nuaire Inc. for laboratory equipment, Sartorius Stedim North America for bioprocess systems, Bio-Rad Laboratories for imaging systems, Mitchell Group Inc. for operational support, and the University of Pittsburgh for primate research services and influenza challenge studies. The vendor also partners with academic institutions — Stanford University and Children's Hospital of Philadelphia received sub-awards for specialized research activities.

The recompete cliff is substantial. Seventy awards with combined potential value of $2.23 billion reach ultimate completion within the next twenty-four months, creating significant recompete exposure. The largest vulnerable awards are task orders against the two master FFRDC vehicles — the NCI and NIAID operational task orders dominating the portfolio complete or require renewal within that window.

Leidos Biomedical Research Inc. is entirely dependent on the NIH ecosystem and specifically on two master FFRDC relationships (NCI and NIAID). The company does not compete for work outside the federal biomedical research and health research and development space, and does not hold positions on government-wide acquisition contracts, schedules, or other multi-vendor vehicles. Its revenue is structured as recurring delivery orders under existing indefinite delivery contracts rather than new competitive wins. The parent company, Leidos Holdings Inc., is a large federal contractor with multi-billion-dollar portfolio; the Biomedical Research subsidiary functions as a specialized operating unit serving health and life sciences agencies exclusively.